Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment

Immune Checkpoint Inhibitors (ICIs) are improving the survival of cancer patients, however only the 20-30% of treated patients present clinical benefits. Toxicity represents the major cause of reduced dosage, delayed drug administration and therapy discontinuation. Hence in the context of multiple t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Botticelli, Andrea, Zizzari, Ilaria, Mazzuca, Federica, Ascierto, Paolo Antonio, Putignani, Lorenza, Marchetti, Luca, Napoletano, Chiara, Nuti, Marianna, Marchetti, Paolo
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5352451/
https://ncbi.nlm.nih.gov/pubmed/27806346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12985
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados